Panel Discussion: Clinical Perspectives on Positioning Antifibrotics in a Post-GLP-1 World
Time: 5:00 pm
day: Conference Day One
Details:
As GLP-1 receptor agonists continue to redefine the treatment landscape for metabolic diseases, antifibrotic developers face mounting pressure to demonstrate clinical value beyond metabolic control. This panel explores the evolving expectations for antifibrotic therapies in MASH and beyond, as well as the implications of real-world GLP-1 usage.
Key Questions for Discussion:
- Who are the patients not responding that would benefit from additional therapeutic?
- How do we position these therapeutics to help the most people in the context of the new approvals?
- What does combination therapy look like in the post-GLP-1 world? How must antifibrotics differentiate themselves and prove additive value?
- Do GLP-1s sufficiently address fibrotic burden in MASH patients with moderate-to severe disease (F2–F4), or is there still a clear need for targeted antifibrotics?
- What happens to fibrosis progression in patients who discontinue GLP-1s? Are we underestimating the risk of rebound pathology?
- How can clinical trials be designed to account for the variability in GLP-1 exposure, adherence, and metabolic response in real-world populations?
